This led us to hypothesize that the decrease in SCFAs might drive FD-mediated impairment of intestinal and systemic immunity by altering a fundamental mechanism that types I and III immune responses have in common, such as CD4+ T cell metabolism15,34. Here, CD4 is linked to Fabry disease.